Cherie Myatt Takes the Helm as Interim President of Vaniam Group

Cherie Myatt's Appointment Marks a Strategic Move for Vaniam Group

In an official announcement made on February 19, 2026, Vaniam Group revealed Cherie Myatt has been appointed as the company's Interim President, effective immediately. With her extensive experience and unique skill set, Myatt is poised to guide the organization during this pivotal time.

Myatt, known for her entrepreneurial background and leadership abilities, expressed her enthusiasm for her new role, stating, "I'm excited to help shape the next phase of Vaniam Group's growth." She articulated her commitment to integrating insights and engagement, underscoring a holistic approach that aligns with the company’s oncology intelligence platform and aims to deepen their impact for clients.

As Interim President, Myatt will take on the responsibility of providing executive leadership across Vaniam Group. This role will include steering the strategic direction of the company, enhancing operational excellence, and ensuring that the firm remains aligned with its long-term vision during its growth journey. She intends to closely collaborate with the leadership team to strengthen momentum and alignment within the organization.

In addition to her responsibilities as Interim President, Cherie Myatt also leads the Patient Engagement and Rare Disease capabilities at Vaniam Group. In this capacity, she has honed a strategic approach to patient-centric innovation, which is critical within the life sciences sector. Myatt's dual roles position her uniquely to promote an integrated strategy that the organization values highly.

Cherie Myatt is not new to the healthcare landscape; she previously founded CM Group, a company that played a crucial role in patient engagement before it was acquired by OPEN Health. Following the acquisition, she continued to expand patient engagement capabilities globally, bringing a unique mix of entrepreneurial spirit and operational expertise that is often hard to come by.

Her impressive track record of building high-performing teams and successfully navigating complex organizational transitions showcases her ability to translate strategic initiatives into tangible results. Deanna van Gestel, the CEO of Vaniam Group, expressed confidence in Myatt's leadership, stating, "Cherie is a proven leader with a rare combination of founder insight and enterprise operating experience. Her appointment as Interim President reflects the confidence we have in her judgment, leadership, and ability to guide our organization with clarity and stability."

This leadership transition signals a deliberate move by Vaniam Group to maintain thoughtful leadership and continuity as it advances toward its long-term goal of value creation. As an oncology-focused partner to biopharmaceutical companies, Vaniam Group is dedicated to providing informed insights and responses to the complexities of high-science medicine in oncology and hematology.

Vaniam Group aims to support its clients in making confident, data-driven decisions as they navigate the evolving landscape of life sciences. As Myatt steps into her role, her commitment to maintaining this standard remains at the forefront of the organization's objectives. By capitalizing on her skills, Vaniam Group intends to further enhance its integration of scientific insights and medical community collaboration, ensuring a comprehensive support system for teams engaged in drug development and related processes.

As candidates for leadership roles in high-stakes environments, figures like Cherie Myatt underscore the importance of experience and innovative thinking in steering organizations toward success. With her at the helm, Vaniam Group is looking to embrace new challenges that come with the rapidly changing landscape of healthcare.

In summary, Cherie Myatt's appointment as Interim President is not just a leadership change but a strategic maneuver aimed at bolstering Vaniam Group's future prospects in the healthcare and oncology sectors. Her leadership is expected to reinforce the company's mission, ensuring that it continues to provide high-value services and insights to its clients, paving the way for sustained success in upcoming years.